Please login to the form below

Not currently logged in
Email:
Password:

Revolade

This page shows the latest Revolade news and features for those working in and with pharma, biotech and healthcare.

Sobi set to spend up to $915m to acquire Dova Pharmaceuticals

Sobi set to spend up to $915m to acquire Dova Pharmaceuticals

The drug is in the same class as Novartis’ big earner Promacta/Revolade (eltrombopag) which is used to treat low platelet levels caused by hepatitis C virus infection, as well as ... The US biotech is continuing to target Revolade’s territory, and if

Latest news

  • CHMP backs Bayer’s tumour-agnostic drug Vitrakvi CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

    look at two other recent rejections – Novartis’ Revolade (eltrombopag) for severe aplastic anaemia and PTC Therapeutics’ Duchenne muscular dystrophy drug Translarna (ataluren).

  • FDA clears Dova drug for liver-related low blood platelets FDA clears Dova drug for liver-related low blood platelets

    Drug is in the same class as Novartis’ Promacta/Revolade. Dova Pharmaceuticals has won its first product approval, getting a green light from the FDA for Doptelet as a treatment for ... Doptelet is in the same class as Novartis’ Promacta/Revolade

  • Novartis’ Promacta receives US breakthrough therapy designation Novartis’ Promacta receives US breakthrough therapy designation

    Known as Revolade in most countries outside the US, Promacta gained its breakthrough therapy designation following positive data, which 52% of treatment-naïve severe aplastic anaemia (SAA) patients achieved complete response ... Regulatory filings for a

  • CHMP backs orphan drugs Uptravi and Coagadex CHMP backs orphan drugs Uptravi and Coagadex

    new indications for Celgene's multiple myeloma therapy Revlimid (lenalidomide) and Novartis' Revolade (eltrombopag) for idiopathic thrombocytopenic purpura (ITP). ... Revlimid has been backed for the treatment of adult patients with relapsed or

  • Novartis bags EU approvals for three ex-GSK drugs Novartis bags EU approvals for three ex-GSK drugs

    Revolade, Tafinlar and Mekinist all receive regulatory approval. Novartis has been granted EU approvals to three drugs acquired as part of its asset swap deal with GlaxoSmithKline, which closed earlier this ... year. The Swiss company announced this

More from news
Approximately 7 fully matching, plus 11 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics